Penbrook Management LLC Oncocyte Corp Transaction History

Penbrook Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 24, 2023	SELL	$0.25 - $15.6 $88,918 - $5.55 Million	-355,675 Reduced 63.14%	207,675 $0
Q3 2022 Oct 31, 2022	SELL	$0.76 - $15.98 $9,424 - $198,152	-12,400 Reduced 2.15%	563,350 $411,000
Q2 2022 Jul 29, 2022	SELL	$0.86 - $1.53 $2,064 - $3,672	-2,400 Reduced 0.42%	575,750 $518,000
Q4 2021 Jan 10, 2022	BUY	$2.04 - $3.59 $1,938 - $3,410	950 Added 0.16%	578,150 $1.26 Million
Q3 2021 Oct 26, 2021	BUY	$3.53 - $5.89 $548,650 - $915,453	155,425 Added 36.85%	577,200 $2.06 Million
Q2 2021 Jul 27, 2021	SELL	$3.77 - $6.0 $7,540 - $12,000	-2,000 Reduced 0.47%	421,775 $2.42 Million
Q1 2021 May 05, 2021	BUY	$2.39 - $6.5 $471,666 - $1.28 Million	197,350 Added 87.16%	423,775 $2.2 Million
Q1 2021 Apr 16, 2021	SELL	$2.39 - $6.5 $471,666 - $1.28 Million	-197,350 Reduced 46.57%	226,425 $555,000
Q4 2020 Jan 27, 2021	BUY	$1.38 - $2.63 $268,203 - $511,140	194,350 Added 84.71%	423,775 $1.01 Million
Q3 2020 Oct 23, 2020	BUY	$1.2 - $1.89 $16,560 - $26,082	13,800 Added 6.4%	229,425 $319,000
Q1 2020 Apr 14, 2020	BUY	$1.76 - $3.02 $68,194 - $117,015	38,747 Added 21.91%	215,625 $529,000
Q4 2019 Jan 16, 2020	BUY	$1.51 - $2.27 $267,085 - $401,513	176,878 New	176,878 $398,000

411K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $294M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Penbrook Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penbrook Management LLC with notifications on news.